Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
April 01 2024 - 4:05PM
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN)
today announced that it will report its first quarter 2024
financial and operating results on Thursday, May 2, 2024, before
the U.S. financial markets open. The Company will host a conference
call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the
’Investors and Media’ page of Regeneron’s website
at https://investor.regeneron.com. To participate via
telephone, please register in advance at this link. Upon
registration, all telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number along with a unique passcode and
registrant ID that can be used to access the call. A replay and
transcript of the conference call and webcast will be archived on
the Company’s website for at least 30 days.
About Regeneron Regeneron is a
leading biotechnology company that invents, develops, and
commercializes life-transforming medicines for people with serious
diseases. Founded and led for over 35 years by
physician-scientists, Regeneron's unique ability to repeatedly and
consistently translate science into medicine has led to numerous
FDA-approved treatments and product candidates in development,
almost all of which were homegrown in Regeneron's
laboratories. Regeneron's medicines and pipeline are designed
to help patients with eye diseases, allergic and inflammatory
diseases, cancer, cardiovascular and metabolic
diseases, hematologic conditions, infectious diseases, and
rare diseases.
Regeneron is accelerating and improving the
traditional drug development process through its
proprietary VelociSuite® technologies, such
as VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully
human antibodies and bispecific antibodies, and through
ambitious research initiatives such as the Regeneron Genetics
Center®, which is conducting one of the largest genetics sequencing
efforts in the world.
For additional information about Regeneron, please
visit www.regeneron.com or follow Regeneron on
LinkedIn.
Contact Information: Investor
Relations Ryan Crowe 914.847.8790 ryan.crowe@regeneron.com
Corporate Communications Christina Chan
914.847.8827 christina.chan@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024